300 episodi
GRACEcast Lung Cancer Video cancerGRACE - H. Jack West, MD
-
- Scienze
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
-
- video
Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?
Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.
-
- video
Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?
The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.
-
- video
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?
Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.
-
- video
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
-
- video
Zykadia for ALK Positive Lung Cancer: New Drug, New Hope
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
-
- video
What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).
Top podcast nella categoria Scienze
Altri contenuti di GRACEcast